Cargando…

Ceftazidime/avibactam for specified infections

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2020
Materias:	New Drugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358056/ https://www.ncbi.nlm.nih.gov/pubmed/32675913 http://dx.doi.org/10.18773/austprescr.2020.028

Ejemplares similares

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
por: Rahmati, Elham, et al.
Publicado: (2017)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Isavuconazole for invasive fungal infections
Publicado: (2020)

Fostemsavir for HIV-1 infection
Publicado: (2022)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
por: Daikos, George L., et al.
Publicado: (2021)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment
por: Wang, Lin, et al.
Publicado: (2022)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
por: Alraddadi, Basem M., et al.
Publicado: (2019)

Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections
por: Tan, Che-Kim, et al.
Publicado: (2019)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
por: Yu, Wei, et al.
Publicado: (2021)

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam
por: Xiong, Luying, et al.
Publicado: (2022)

Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
por: Cui, Qiaozhen, et al.
Publicado: (2023)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
por: Li, Dan, et al.
Publicado: (2021)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2020)

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
por: Cui, Xiaoyan, et al.
Publicado: (2020)

Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam
por: Bassetti, Matteo, et al.
Publicado: (2020)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
por: Das, Shampa, et al.
Publicado: (2019)

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
por: Huang, Yanqin, et al.
Publicado: (2021)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
por: Mancuso, Alessandro, et al.
Publicado: (2023)

Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study
por: Zheng, Guanhao, et al.
Publicado: (2021)

Brolucizumab for macular degeneration
Publicado: (2020)

Galcanezumab for migraine
Publicado: (2020)

Semaglutide for type 2 diabetes
Publicado: (2020)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Darolutamide for prostate cancer
Publicado: (2020)

Remdesivir for COVID-19
Publicado: (2020)

Upadacitinib for rheumatoid arthritis
Publicado: (2020)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Stiripentol for Dravet syndrome
Publicado: (2020)

Abemaciclib for breast cancer
Publicado: (2020)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Fremanezumab for migraine
Publicado: (2020)

Teduglutide for short bowel syndrome
Publicado: (2020)

Risankizumab for psoriasis
Publicado: (2020)

Lorlatinib for non-small cell lung cancer
Publicado: (2020)

Polatuzumab vedotin for B-cell lymphoma
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6l9tj8p6u0je0k83b41hp4v8gv